Montelukast as a potential treatment for COVID-19

References

• Marogna M, Colombo F, Spadolini I, et al. Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. J Investig Allergol Clin Immunol. 2010;20(2):146–152.
   PubMedGoogle Scholar
• Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol. 2010;32(9):669–674.
   PubMedGoogle Scholar
• Rabinovitch N, Graber NJ, Chinchilli VM, et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol. 2010;126(3):545–51.e1–4.
   Google Scholar
• Wu Y, Cui C, Bi FF, et al. Montelukast, cysteinyl leukotriene receptor 1 antagonist, inhibits cardiac fibrosis by activating APJ. Eur J Pharmacol. 2022;923:174892.
   PubMedGoogle Scholar
• Esmaeilzadeh H, Far NM, Nabavizadeh SH, et al. Study of montelukast and azelastine add on therapy in moderate to severe allergic rhinitis treatment: a double-blind randomized clinical trial. Am J Rhinol Allergy. 2022;36(5):559–567.
   PubMedGoogle Scholar
• Davino-Chiovatto JE, Oliveira-Junior MC, MacKenzie B, et al. Montelukast, leukotriene inhibitor, reduces LPS-induced acute lung inflammation and human neutrophil activation. Arch Bronconeumol (Engl Ed). 2019;55(11):573–580.
   PubMed Web of Science ®Google Scholar
• Gelosa P, Bonfanti E, Castiglioni L, et al. Improvement of fiber connectivity and functional recovery after stroke by montelukast, an available and safe anti-asthmatic drug. Pharmacol Res. 2019;142:223–236.
   PubMedGoogle Scholar
• Kawai Y, Narita Y, Yamawaki-Ogata A, et al. Montelukast, a cysteinyl leukotriene receptor 1 antagonist, induces M2 macrophage polarization and inhibits murine aortic aneurysm formation. Biomed Res Int. 2019;2019:9104680.
   PubMedGoogle Scholar
• Marques CF, Marques MM, Justino GC. Leukotrienes vs. montelukast-activity, metabolism, and toxicity hints for repurposing. Pharmaceuticals (Basel). 2022;15:9.
   Google Scholar
• Sanghai N, Tranmer GK. Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms. Drug Discov Today. 2020;25(12):2076–2079.
   PubMed Web of Science ®Google Scholar
• Zanfirescu A, Nitulescu G, Mihai DP, et al. Identifying FAAH inhibitors as new therapeutic options for the treatment of chronic pain through drug repurposing. Pharmaceuticals (Basel). 2021;15:1.
   PubMedGoogle Scholar
• Camera M, Canzano P, Brambilla M, et al. Montelukast inhibits platelet activation induced by plasma from COVID-19 patients. Front Pharmacol. 2022;13:784214.
   PubMedGoogle Scholar
• Durdagi S, Avsar T, Orhan MD, et al. The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies. Mol Ther. 2022;30(2):963–974.
   PubMedGoogle Scholar
• Zhang J, Zou Y, Chen L, et al. Regulatory T cells, a viable target against airway allergic inflammatory responses in asthma. Front Immunol. 2022;13:902318.
   PubMedGoogle Scholar
• Paoletti G, Pepys J, Casini M, et al. Biologics in severe asthma: the role of real-world evidence from registries. Eur Respir Rev. 2022;31:164.
   Google Scholar
• Moral L, Asensi Monzó M, Juliá Benito JC, et al. Pediatric asthma: the REGAP consensus. An Pediatr (Engl Ed). 2021;95(2):125.e1–.e11.
   PubMedGoogle Scholar
• Demet Akbaş E, Razi CH, Andıran N. Effects of using montelukast during acute wheezing attack in hospitalized preschool children on the discharge rate and the clinical asthma score. Pediatr Pulmonol. 2021;56(7):1931–1937.
   PubMedGoogle Scholar
• Dorscheid DR, Lee JK, Ramesh W, et al. Guidance for administering biologics for severe asthma and allergic conditions. Can Respir J. 2022;2022:9355606.
   PubMedGoogle Scholar
• Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med. 2006;100(11):1952–1959.
   PubMed Web of Science ®Google Scholar
• Kemp JP. Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med. 2003;2(2):139–156.
   PubMedGoogle Scholar
• Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339(3):147–152.
   PubMed Web of Science ®Google Scholar
• Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J. 1998;11(6):1232–1239.
   PubMed Web of Science ®Google Scholar
• Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108(3):E48.
   PubMed Web of Science ®Google Scholar
• Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. montelukast clinical research study group. Arch Intern Med. 1998;158(11):1213–1220.
   PubMed Web of Science ®Google Scholar
• Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric montelukast study group. JAMA. 1998;279(15):1181–1186.
   PubMed Web of Science ®Google Scholar
• Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy. 2001;31(1):77–87.
   PubMed Web of Science ®Google Scholar
• Philip G, Pedinoff A, Vandormael K, et al. A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma. J Asthma. 2010;47(10):1078–1084.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung TF, Leung AK. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug Des Devel Ther. 2014;8:839–850.
   PubMed Web of Science ®Google Scholar
• Ebrahim N, Mandour YMH, Farid AS, et al. Adipose tissue-derived mesenchymal stem cell modulates the immune response of allergic rhinitis in a rat model. Int J Mol Sci. 2019;20:4.
   Google Scholar
• Dalgic A, Dinc ME, Ulusoy S, et al. Comparison of the effects of nasal steroids and montelukast on olfactory functions in patients with allergic rhinitis. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134(4):213–216.
   PubMedGoogle Scholar
• de Souza Campos Fernandes S, Ribeiro de Andrade C, da Cunha Ibiapina C. Application of peak nasal inspiratory flow reference values in the treatment of allergic rhinitis. Rhinology. 2014;52(2):133–136.
   PubMedGoogle Scholar
• Polos PG. Montelukast is an effective monotherapy for mild asthma and for asthma with co-morbid allergic rhinitis. Prim Care Respir J. 2006;15(5): 310–1;author reply 1–2.
   PubMedGoogle Scholar
• Portnoy JM, Van Osdol T, Williams PB. Evidence-based strategies for treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2004;4(6):439–446.
   PubMedGoogle Scholar
• Sardana N, Santos C, Lehman E, et al. A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the rhinitis severity score. Allergy Asthma Proc. 2010;31(1):5–9.
   PubMed Web of Science ®Google Scholar
• Sardana N, Craig TJ. Congestion and sleep impairment in allergic rhinitis. Asian Pac J Allergy Immunol. 2011;29(4):297–306.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Ma D, Zhu Q, et al. Effect of azelastine hydrochloride combined with montelukast sodium in the treatment of patients with allergic rhinitis. Am J Transl Res. 2021;13(8):9570–9577.
   PubMedGoogle Scholar
• DuBuske LM. Mediator antagonists in the treatment of allergic disease. Allergy Asthma Proc. 2001;22(5):261–275.
   PubMedGoogle Scholar
• Bhattachan S, Neupane Y, Pradhan B, et al. Comparison of outcomes between mometasone furoate intranasal spray and oral montelukast in patients with allergic rhinitis. J Nepal Health Res Counc. 2020;18(2):268–270.
   PubMedGoogle Scholar
• Guo-Zhu H, Xi-Ling Z, Zhu W, Li-Hua W, Dan H, Xiao-Mu W, et al. Therapeutic potential of combined anti-IL-1β IgY and anti-TNF-α IgY in Guinea pigs with allergic rhinitis induced by ovalbumin. Int Immunopharmacol. 2015;25(1):155–161.
   PubMedGoogle Scholar
• Haberal I, Corey JP. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg. 2003;129(3):274–279.
   PubMedGoogle Scholar
• Nishimura T, Kaminuma O, Saeki M, et al. Effects of anti-allergic drugs on T cell-mediated nasal hyperresponsiveness in a murine model of allergic rhinitis. Allergol Int. 2018;67S:S25–S31.
   PubMedGoogle Scholar
• Sacre Hazouri JA. [Leukotriene antagonists in the treatment of allergic rhinitis and comorbidities]. Rev Alerg Mex. 2008;55(4):164–175.
   PubMedGoogle Scholar
• van Adelsberg J, Philip G, LaForce CF, et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90(2):214–222.
   PubMed Web of Science ®Google Scholar
• Nayak AS, Philip G, Lu S, Malice MP, Reiss TF, Group MFRI. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88(6):592–600.
   PubMedGoogle Scholar
• Mullol J, Callejas FB, Méndez-Arancibia E, et al. Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. J Biol Regul Homeost Agents. 2010;24(4):403–411.
   PubMed Web of Science ®Google Scholar
• McCarthy MW. Treatment of severe COVID-19: an evolving paradigm. Expert Opin Pharmacother. 2022;23(17):1887–1891.
   Google Scholar
• Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635–641.
   PubMed Web of Science ®Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Almulaiky YQ, et al. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: the enigmatic entity. Eur J Pharmacol. 2021;904:174196.
   PubMed Web of Science ®Google Scholar
• Kerget B, Kerget F, Aydın M, et al. Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19. J Med Virol. 2022;94(5):1950–1958.
   PubMedGoogle Scholar
• Khan AR, Misdary C, Yegya-Raman N, et al. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2022;59(4):780–786.
   PubMed Web of Science ®Google Scholar
• Blondon M, Cereghetti S, Pugin J, et al. Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: the Swiss COVID-HEP randomized clinical trial. Res Pract Thromb Haemost. 2022;6(4):e12712.
   PubMedGoogle Scholar
• Donato AA. In critically ill patients with COVID-19, therapeutic anticoagulation did not increase organ support-free days. Ann Intern Med. 2021;174(12):JC135.
   PubMed Web of Science ®Google Scholar
• Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–789.
   PubMed Web of Science ®Google Scholar
• Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385(9):790–802.
   Google Scholar
• Collins FS, Accelerating SP. COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA. 2020;323(24):2455–2457.
   PubMed Web of Science ®Google Scholar
• Naggie S, Boulware DR, Lindsell CJ, et al. Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;328(16):1595–1603.
   PubMed Web of Science ®Google Scholar
• LaVange L, Adam SJ, Currier JS, et al. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): designing master protocols for evaluation of candidate COVID-19 therapeutics. Ann Intern Med. 2021;174(9):1293–1300.
   PubMed Web of Science ®Google Scholar
• Collignon O, Burman CF, Posch M, et al. Collaborative platform trials to fight COVID-19: methodological and regulatory considerations for a better societal outcome. Clin Pharmacol Ther. 2021;110(2):311–320.
   PubMed Web of Science ®Google Scholar
• Luedemann M, Stadler D, Cheng CC, et al. Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. Comput Struct Biotechnol J. 2022;20:799–811.
   PubMedGoogle Scholar
• Soltani R, Nasirharandi S, Khorvash F, et al. The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID-19- related cough: a randomized, controlled clinical trial. Clin Respir J. 2022;16(9):604–610.
   PubMedGoogle Scholar
• McCarthy MW. Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). Expert Opin Pharmacother. 2022;23(5):623–628.
   PubMed Web of Science ®Google Scholar
• Bozek A, Winterstein J. Montelukast’s ability to fight COVID-19 infection. J Asthma. 2021;58(10):1348–1349.
   PubMed Web of Science ®Google Scholar
• Dey M, Singh RK. Possible therapeutic potential of cysteinyl leukotriene receptor antagonist montelukast in treatment of SARS-CoV-2-induced COVID-19. Pharmacology. 2021;106(9–10):469–476.
   PubMedGoogle Scholar
• Mera-Cordero F, Bonet-Monne S, Almeda-Ortega J, et al. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: e-SPERANZA COVID Project study protocol. Trials. 2022;23(1):19.
   PubMedGoogle Scholar
• Chen Y, Wang X, Shi H, et al. Montelukast inhibits HCoV-OC43 infection as a viral inactivator. Viruses. 2022 Apr 21;14(5):861.
   PubMedGoogle Scholar